Skip to search formSkip to main contentSkip to account menu

rhAPC

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

drotrecogin alfa

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
Recombinant human activated protein C as a disease modifier in severe acute pancreatitis: systematic review of current evidence.
Review
2009
Review
2009
Safety of drotrecogin alfa (activated) in severe sepsis: data from adult clinical trials and observational studies.
2008
2008
Thromboembolic complications of sepsis: What is the incidence and pathophysiological mechanisms involved?
Thromboembolic complications of sepsis: What is the incidence and pathophysiological mechanisms involved? - 
Highly Cited
2007
Highly Cited
2007
Increasing evidence that the risks of rhAPC may outweigh its benefits
Received: 24 January 2007Accepted: 24 January 2007© Springer-Verlag 2007This editorial refers to the articles available at:http… 
2007
2007
The respective and combined anticoagulant effects of recombinant human activated protein C, melagatran and heparins using CAT.
Review
2007
Review
2007
Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis
BackgroundActivated drotrecogin alfa (human activated protein C, rhAPC), is produced by recombinant DNA technology, and purports… 
2005
2005
Protein S modulates the anticoagulant action of recombinant human activated protein C: a comparison between neonates and adults
Recombinant human‐activated protein C (rhAPC, Drotrecogin alpha (activated), Xigris™) has been shown to reduce organ damage and… 
2004
2004
Drotrecogin alfa (activated) inhibits NF-kappa B activation and MIP-1-alpha release from isolated mononuclear cells of patients with severe sepsis
Abstract.Objective and design: Non-anticoagulant biological activities, such as anti-inflammatory and anti-apoptotic mechanisms… 
2003
2003
Clinical and laboratory effects of recombinant human activated protein C in the treatment of a patient with sepsis-induced multiple organ failure.
Review
2002
Review
2002
Coagulation inhibitors in the treatment of sepsis
Despite advances in supportive care, sepsis and septic shock continue to be major causes of morbidity and mortality in critically… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)